Fifth Third Bancorp
SNDX icon

Fifth Third Bancorp’s Syndax Pharmaceuticals SNDX Stock Holding History

Fifth Third Bancorp’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15K Sell
687
-311
-31% -$6.47K ﹤0.01% 3630
2026
Q1 		$23.3K Buy
+998
New +$21.7K ﹤0.01% 3454

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Fifth Third Bancorp's SNDX Position: Q2 2026 in Review

Fifth Third Bancorp reduced its Syndax Pharmaceuticals (SNDX) stake by 31% in Q2 2026, selling an estimated $6.47K and leaving 687 shares worth $15K. The position accounts for ﹤0.01% of the portfolio, ranked #3630.

Fifth Third Bancorp first reported a position in SNDX in Q1 2026 and has held it in 2 quarters since. The position peaked at $23.3K in Q1 2026. 243 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Fifth Third Bancorp held 687 shares of Syndax Pharmaceuticals worth $15K as of Q2 2026.
  • Fifth Third Bancorp sold 311 Syndax Pharmaceuticals shares in Q2 2026, an estimated $6.47K.
  • Syndax Pharmaceuticals made up ﹤0.01% of Fifth Third Bancorp's portfolio in Q2 2026, its #3630 holding.
  • Fifth Third Bancorp first reported a position in Syndax Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Fifth Third Bancorp's Syndax Pharmaceuticals position peaked at $23.3K in Q1 2026.
  • 243 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Fifth Third Bancorp's 13F filing for Q2 2026, filed 5 Aug 2026.